Medical Condition News

RSS

Study reveals association between sleep-disordered breathing and Alzheimer's disease

Alzheimer's disease affects millions of people worldwide. As a result of an increase in life expectancy, the number of patients with dementia is expected to increase dramatically. Due to the lack of effective treatments that can slow down or reverse the progression of AD, preventive measures to lower the prevalence rate of AD by means of managing potential or actual risk factors is a reasonable clinical strategy.

9 Oct 2013

ProTip, Strasbourg University Hospitals complete first implantation of artificial larynx in human patient

ProTip SAS, the specialist developer of innovative medical devices for patients suffering from laryngeal malfunction, and Strasbourg University Hospitals today announce that they have successfully completed the first implantation of an artificial larynx in a human patient.

9 Oct 2013

NeuroVigil opens satellite research lab at NASA to develop assistive technologies for ALS

NeuroVigil, Inc. is setting to collaborate with a number of partners in the Silicon Valley where it is opening a satellite research laboratory at NASA Research Park in Mountain View, CA, to develop assistive technologies for individuals suffering from ALS and other conditions affecting the central nervous system.

9 Oct 2013

Two gene mutations associated with increased risk of developing eating disorders

Eating disorders like anorexia nervosa and bulimia often run in families, but identifying specific genes that increase a person's risk for these complex disorders has proved difficult.

9 Oct 2013

Survey reveals 60% of Americans report of having Silicon Valley Syndrome

LUMO BodyTech, the makers of the LUMOback smart posture and movement feedback system, today announced national survey results revealing a widespread phenomenon LUMO calls 'Silicon Valley Syndrome'.

9 Oct 2013

Mitsubishi Electric to provide proton beam therapy system to Hakuhokai Group healthcare organization

Mitsubishi Electric Corporation announced today that it will provide its innovative proton beam therapy system for cancer treatment to the Hakuhokai Group healthcare organization led by Chairman Motohisa Kojo in Osaka, Japan. The system will be installed at the Hakuhokai Group Osaka Proton Therapy Clinic scheduled to open in April 2016.

9 Oct 2013

EGS announced that enrollment for RESPECT study has surpassed company's original target

EndoGastric Solutions (EGS), the leader in endoluminal reconstructive treatment for gastroesophageal reflux disease (GERD), announced today that enrollment for the RESPECT study (Randomized EsophyX vs. Sham/Placebo Controlled Trial) is complete and has surpassed the company's original target of 120 patients.

9 Oct 2013

Bayer HealthCare receives FDA approval for Adempas tablets

Bayer HealthCare announced today that the United States Food and Drug Administration has approved Adempas (riociguat) tablets for: (i) the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class; and (ii) the treatment of adults with pulmonary arterial hypertension (WHO Group 1) to improve exercise capacity, improve WHO functional class and delay clinical worsening.

9 Oct 2013

Edimer doses first XLHED-affected neonate in Phase 2 trial of EDI200

Edimer Pharmaceuticals, a biotechnology company focused on developing an innovative therapy for the rare genetic disorder X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), today announced the enrollment and completed dosing of the first XLHED-affected neonate in a Phase 2 trial of EDI200, the company's novel, proprietary, recombinant protein.

9 Oct 2013

Alkermes completes patient enrollment in phase 3 study of aripiprazole lauroxil in schizophrenia patients

Alkermes plc (NASDAQ: ALKS) today announced completion of patient enrollment in the pivotal, multinational phase 3 study evaluating aripiprazole lauroxil in patients with schizophrenia.

9 Oct 2013

Quintiles and MDA partner to develop U.S. Neuromuscular Disease Registry

Quintiles and the Muscular Dystrophy Association (MDA) today announced a new partnership to develop and implement the U.S. Neuromuscular Disease Registry, a patient registry that will play an important role in determining effective treatments for people with muscular dystrophy and related muscle diseases.

9 Oct 2013

Moximed initiates pivotal trial of KineSpring System implantation in knee osteoarthritis patients

Moximed, Inc. announced today that the KineSpring® System, an implantable medical spring for knee osteoarthritis that works by unloading the weight on the diseased joint, has been successfully implanted in the first patients enrolled in the UK arm of its multi-centre GOAL study.

9 Oct 2013

ReAttach therapy can be effective treatment for people with autism

"ReAttach" is a new intervention, based on "attachment". Practical research has pointed out that the "ReAttach therapy" can be of great importance for people with autism. This is concluded from the continuous practical research of Paula Bartholomeus into the advantages that can be reached for people with Asperger's syndrome, PDD-NOS, autism spectrum disorder, or with a mental disability and autism, using the ReAttach therapy.

9 Oct 2013

Alnylam advances Development Candidate for ALN-AS1 for treatment of hepatic porphyrias

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it is advancing its Development Candidate for ALN-AS1, an RNAi therapeutic targeting aminolevulinate synthase-1 (ALAS-1) for the treatment of hepatic porphyrias including acute intermittent porphyria (AIP).

9 Oct 2013

Acorda Therapeutics initiates second clinical trial of Glial Growth Factor 2 in heart failure patients

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the first patient has been enrolled in the second clinical trial of Glial Growth Factor 2 (GGF2). This Phase 1b single-infusion trial in people with heart failure will assess tolerability of three dose levels of GGF2, and also includes several explorative measures of efficacy.

9 Oct 2013

MRFBC launches clinical trial to assess impact of bevacizumab and vemurafenib in melanoma patients

The Melanoma Research Foundation Breakthrough Consortium has launched a new clinical trial to assess the impact of concomitant administration of bevacizumab (Avastin) with vemurafenib (Zelboraf) in patients with BRAFV600 mutation positive metastatic melanoma.

8 Oct 2013

LSTM professor wins Universal Biotech Innovation Prize 2013 for Hexagard

Professor Richard Pleass has won the Prix de l’Innovation 2013, also known as the Universal Biotech Innovation Prize 2013.

8 Oct 2013

Brain & Behavior Research Foundation to hold research symposium on mental health

The Brain & Behavior Research Foundation, an organization dedicated to improving the lives of those with mental illness through the transformative power of neuroscience and psychiatric research, will hold its 25th Annual Mental Health Research Symposium on Friday, October 25th from 9:00 am to 4:30 p.m. at the Kaufman Music Center, located at 129 W. 67th St. in New York City.

8 Oct 2013

New stand-alone intervertebral body fusion device gets FDA clearance

Surgeons treating patients with degenerative disc disease may now use a new stand-alone intervertebral body fusion device recently cleared by the Food and Drug Administration. Manufactured by Binder Biomedical Inc., the device presents a complete anterior lumbar fixation system with a simple, one-step locking mechanism.

8 Oct 2013

Publication provides update on the origins and causes of anxiety disorders

Anxiety disorders are not uncommon and are often 'comorbid' with other forms of mental disorders. This publication provides an update on the origins and the causes of anxiety disorders and their related symptoms.

8 Oct 2013

Medical Condition News

Study reveals association between sleep-disordered breathing and Alzheimer's disease

ProTip, Strasbourg University Hospitals complete first implantation of artificial larynx in human patient

NeuroVigil opens satellite research lab at NASA to develop assistive technologies for ALS

Two gene mutations associated with increased risk of developing eating disorders

Survey reveals 60% of Americans report of having Silicon Valley Syndrome

Mitsubishi Electric to provide proton beam therapy system to Hakuhokai Group healthcare organization

EGS announced that enrollment for RESPECT study has surpassed company's original target

Bayer HealthCare receives FDA approval for Adempas tablets

Edimer doses first XLHED-affected neonate in Phase 2 trial of EDI200

Alkermes completes patient enrollment in phase 3 study of aripiprazole lauroxil in schizophrenia patients

Quintiles and MDA partner to develop U.S. Neuromuscular Disease Registry

Moximed initiates pivotal trial of KineSpring System implantation in knee osteoarthritis patients

ReAttach therapy can be effective treatment for people with autism

Alnylam advances Development Candidate for ALN-AS1 for treatment of hepatic porphyrias

Acorda Therapeutics initiates second clinical trial of Glial Growth Factor 2 in heart failure patients

MRFBC launches clinical trial to assess impact of bevacizumab and vemurafenib in melanoma patients

LSTM professor wins Universal Biotech Innovation Prize 2013 for Hexagard

Brain & Behavior Research Foundation to hold research symposium on mental health

New stand-alone intervertebral body fusion device gets FDA clearance

Publication provides update on the origins and causes of anxiety disorders

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News